Aldose reductase inhibitors may represent a therapeutic strategy to limit myocardial ischemic injury and improve functional recovery during reperfusion.
Answers are grounded in this paper and cite their sources.
May support aldose reductase inhibition for ischemia-reperfusion; hypothesis-generating and leaves open clinical translation.
In Brief KANEKO, M., and R. RAMASAMY. Aldose reductase: A key player in myocardial ischemic injury. Exerc. Sport Sci. Rev., Vol. 32, No. 1, pp. 19–23, 2004. In the search for increasing effectiveness of reperfusion therapy, the authors demonstrate that the polyol pathway enzyme aldose reductase is a key component of myocardial ischemic injury and that inhibitors of this enzyme limit ischemic injury and improve functional recovery on reperfusion. Aldose reductase is a key component of myocardial ischemic injury. Inhibitors of this enzyme reduce ischemic injury and improve contractile function recovery.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: